The Medicines Control Authority of Zimbabwe on Monday announced the approval of the use of long-acting injectable cabotegravir (CAB-LA) as a pre-exposure prophylaxis (PrEP) for HIV prevention, a first for Africa.
Zimbabwe has become the first country in Africa to approve a long-acting injectable drug that prevents HIV transmission.
The first two injections of Cabotegraviror CAB-LA are administered four weeks apart, followed by an injection every eight weeks.
The drug has received regulatory approval in two other countries, the US and Australia.
Zimbabwe will begin rolling out the drug after regulators approved its use. The authorities say it will provide a crucial layer of protection for risk groups.
Large-scale studies of the drug showed a 79% reduction in HIV risk compared with oral pre-exposure prophylaxis, according to the World Health Organisation.
Zimbabwe approved a long-acting HIV-preventative vaginal ring earlier this year.
While African countries have dramatically reduced the number of new HIV infections, adolescent girls and young women remain at risk accounting for 63% of new infections last year.
more recommended stories
Nelson Chamisa rebukes party MPs who accepted government loot
Citizens Coalition for Change (CCC) leader.
Zimbabwe exemption permit case delayed to April 2023
The Helen Suzman Foundation’s (HSF’s) challenge.
Zimbabwe’s imposing new Chinese-funded parliament opens
HARARE, Zimbabwe — Zimbabwean President Emmerson.
Sikhala denied bail, Harare Magistrate says he is an unrepentant criminal
Citizens’ Coalition for Change (CCC) Member.
Zimbabwe 2023 budget expected to consolidate gains
THE Minister of Finance and Economic.
Zimbabwe pregnant nine-year-old girl opens up on rape ordeal
THE mother of the nine-year-old pregnant.
The Commonwealth Secretariat mission to visit Zimbabwe
The Commonwealth Secretariat is today confirming.
Interpo arrest wanted Zimbabwean businessman Frank Buyanga in Sandton
Interpol South Africa and the National.